0781-5175 : Mycophenolate Mofetil 500 mg Oral Tablet


NDC: 0781-5175
Labeler: Sandoz Inc
Product Type: Human Prescription Drug
Drug Name: Mycophenolate Mofetil
Dosage Form: Oral Tablet
Application #: ANDA065451
Rev. Date: 


Appearance:


Markings: SZ;327
Shapes:  Round
Colors:  Red
Size (mm): 18
Segments: * 1

* Segments = the number of equally sized pieces which the pill can be broken into. In this case, a value of 1 indicates a solid pill with no score lines.

NDC Package Codes:

  • 0781-5175-01: 100 TABLET IN 1 BOTTLE (0781‑5175‑01)
  • 0781-5175-05: 500 TABLET IN 1 BOTTLE (0781‑5175‑05)
  • 0781-5175-10: 1000 TABLET IN 1 BOTTLE (0781‑5175‑10)

Active Ingredients:

  • Mycophenolate Mofetil

Dosage Strength:

  • 500 mg

Inactive Ingredients:

  • Croscarmellose Sodium
  • Hydroxypropyl Cellulose
  • Hypromelloses
  • Ferrosoferric Oxide
  • Ferric Oxide Red
  • Magnesium Stearate
  • Cellulose, Microcrystalline
  • Polyethylene Glycols
  • Povidone
  • Talc
  • Titanium Dioxide
  • Croscarmellose Sodium
  • Magnesium Stearate
  • Povidone K90
  • Microcrystalline Cellulose
  • Talc
  • Hypromellose 2910 (5 Mpa.s)
  • Hydroxypropyl Cellulose, Unspecified
  • Titanium Dioxide
  • Ferrosoferric Oxide
  • Ferric Oxide Red
  • Polyethylene Glycol 400 /

Pharmaceutical Classes:

  • Antimetabolite Immunosuppressant [EPC]

Related Products:

Based on records with the same trade name.
  • 0781-2067 Mycophenolate Mofetil 250 mg Oral Capsule by Sandoz Inc
  • 0054-0163 Mycophenolate Mofetil 250 mg Oral Capsule by Roxane Laboratories, Inc
  • 0054-0166 Mycophenolate Mofetil 500 mg Oral Tablet by Roxane Laboratories, Inc
  • 0093-7334 Mycophenolate Mofetil 250 mg Oral Capsule by Teva Pharmaceuticals USA Inc
  • 0093-7477 Mycophenolate Mofetil 500 mg Oral Tablet by Teva Pharmaceuticals USA Inc
  • 0378-2250 Mycophenolate Mofetil 250 mg Oral Capsule by Mylan Pharmaceuticals Inc.
  • 0378-4472 Mycophenolate Mofetil 500 mg Oral Tablet by Mylan Pharmaceuticals Inc.
  • 0480-1175 Mycophenolate Mofetil 200 mg/ml Oral Powder, for Suspension by Teva Pharmaceuticals, Inc.
  • 0480-3571 Mycophenolate Mofetil 500 mg Oral Tablet, Film Coated by Teva Pharmaceuticals USA, Inc.
  • 0527-5160 Mycophenolate Mofetil 200 mg/ml Oral Powder, for Suspension by Lannett Company, Inc.
  • 0904-7074 Mycophenolate Mofetil 250 mg Oral Capsule by Major Pharmaceuticals
  • 0904-7078 Mycophenolate Mofetil 500 mg Oral Tablet, Film Coated by Major Pharmaceuticals
  • 16714-345 Mycophenolate Mofetil 200 mg/ml Oral Powder, for Suspension by Northstar Rxllc
  • 16729-019 Mycophenolate Mofetil 500 mg Oral Tablet by Accord Healthcare Inc.
  • 16729-094 Mycophenolate Mofetil 250 mg Oral Capsule by Accord Healthcare Inc.
  • 17478-422 Mycophenolate Mofetil 500 mg/20ml Intravenous Injection, Powder, Lyophilized, for Solution by Akorn, Inc.
  • 17478-957 Mycophenolate Mofetil 500 mg/20ml Intravenous Injection, Powder, Lyophilized, for Solution by Akorn, Inc.
  • 23155-830 Mycophenolate Mofetil 250 mg Oral Capsule by Avet Pharmaceuticals Inc
  • 23155-836 Mycophenolate Mofetil 500 mg Oral Tablet, Film Coated by Avet Pharmaceuticals Inc
  • 23155-848 Mycophenolate Mofetil 200 mg/ml Oral Powder, for Suspension by Heritage Pharmaceuticals Inc. D/B/A Avet Pharmaceuticals Inc.
  • More related products ...

NDC QR Code

Scan the QR code below to easily reference this data in the future:

NDC 0781-5175 QR Code

< Prev: 0781-5169Next: 0781-5177 >

Related Discussions:

Pomegranate interactions with Tacrolimus and Mycophenolate
Can I take a tonic that includes pomegranate supplement when taking Tacrolimus and Mycophenolate anti-kidney-rejection m... 1 reply
mycophenolate
is it for depression?...




Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.